NightBalance prepares to enter U.S. market
DELFT, Netherlands – NightBalance BV, a manufacturer of obstructive sleep apnea devices, has announced the completion of a EUR 12.5 million Series B financing round led by INKEF Capital and Gilde Healthcare Partners. The proceeds will allow NightBalance to intensify and expand commercial activities for its Sleep Position Trainer in Europe, and to prepare for the company’s entry into the U.S. market. The manufacturer is also planning further clinical studies in the U.S. and filing for 510(k) clearance with the U.S. Food and Drug Administration. John Lipman, former vice president of marketing and commercial development of Apnicure, has been appointed COO U.S. to head NightBalance’s operations here. The Sleep Position Trainer, worn around the upper body, measures the sleep behavior of the patient. Once a patient turns into the supine position, the device gives a gentle vibration, prompting the patient to change sleeping position, all without disrupting the “natural sleeping architecture,” according to the company.